A Zebrafish Model for VHL and Hypoxia Signaling

Methods in Cell Biology

Volumn 105, Issue , 2011, Pages 163-190

  van Rooijen, Ellen ^a,b,c   Santhakumar, Kirankumar ^a   Logister, Ive ^a,b   Voest, Emile ^a   Schulte Merker, Stefan ^b   Giles, Rachel ^c   van Eeden, Fredericus ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Angiogenesis; Biomarker; Hypoxia; Polycythemia; Signaling; Suppressor

Indexed keywords

EID: 80053193618     PISSN: 0091679X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-381320-6.00007-2     Document Type: Chapter

References (152)

1. Adryan B., Decker H.J., Papas T.S., Hsu T. Tracheal development and the von Hippel-Lindau tumor suppressor homolog in Drosophila. Oncogene 2000, 19:2803-2811.
2. Alvarez Y., Cederlund M.L., Cottell D.C., Bill B.R., Ekker S.C., Torres-Vazquez J., Weinstein B.M., Hyde D.R., Vihtelic T.S., Kennedy B.N. Genetic determinants of hyaloid and retinal vasculature in zebrafish. BMC Dev. Biol. 2007, 7:114.
3. Ang S.O., Chen H., Hirota K., Gordeuk V.R., Jelinek J., Guan Y., Liu E., Sergueeva A.I., Miasnikova G.Y., Mole D., Maxwell P.H., Stockton D.W., Semenza G.L., Prchal J.T. Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat. Genet. 2002, 32:614-621.
4. Bahary N., Goishi K., Stuckenholz C., Weber G., Leblanc J., Schafer C.A., Berman S.S., Klagsbrun M., Zon L.I. Duplicate VegfA genes and orthologues of the KDR receptor tyrosine kinase family mediate vascular development in the zebrafish. Blood 2007, 110:3627-3636.
5. Biju M.P., Neumann A.K., Bensinger S.J., Johnson R.S., Turka L.A., Haase V.H. Vhlh gene deletion induces Hif-1-mediated cell death in thymocytes. Mol. Cell. Biol. 2004, 24:9038-9047.
6. Bishop T., Lau K.W., Epstein A.C., Kim S.K., Jiang M., O'Rourke D., Pugh C.W., Gleadle J.M., Taylor M.S., Hodgkin J., Ratcliffe P.J. Genetic analysis of pathways regulated by the von Hippel-Lindau tumor suppressor in Caenorhabditis elegans. PLoS Biol. 2004, 2:e289.
7. Boutin A.T., Weidemann A., Fu Z., Mesropian L., Gradin K., Jamora C., Wiesener M., Eckardt K.U., Koch C.J., Ellies L.G., Haddad G., Haase V.H., Simon M.C., Poellinger L., Powell F.L., Johnson R.S. Epidermal sensing of oxygen is essential for systemic hypoxic response. Cell 2008, 133:223-234.
8. Brugarolas J., Lei K., Hurley R.L., Manning B.D., Reiling J.H., Hafen E., Witters L.A., Ellisen L.W., Kaelin W.G. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev. 2004, 18:2893-2904.
9. Bruick R.K., McKnight S.L. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 2001, 294:1337-1340.
10. Brukamp K., Jim B., Moeller M.J., Haase V.H. Hypoxia and podocyte-specific Vhlh deletion confer risk of glomerular disease. Am. J. Physiol. Renal Physiol. 2007, 293:F1397-F1407.
11. Bussmann J., Lawson N., Zon L., Schulte-Merker S. Zebrafish VEGF receptors: a guideline to nomenclature. PLoS Genet. 2008, 4:e1000064.
12. Carradice D., Lieschke G.J. Zebrafish in hematology: sushi or science?. Blood 2008, 111:3331-3342.
13. Champion K.J., Guinea M., Dammai V., Hsu T. Endothelial function of von Hippel-Lindau tumor suppressor gene: control of fibroblast growth factor receptor signaling. Cancer Res. 2008, 68:4649-4657.
14. Chen F., Kishida T., Yao M., Hustad T., Glavac D., Dean M., Gnarra J.R., Orcutt M.L., Duh F.M., Glenn G., et al. Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. Hum. Mutat. 1995, 5:66-75.
15. Chew E.Y. Ocular manifestations of von Hippel-Lindau disease: clinical and genetic investigations. Trans. Am. Ophthalmol. Soc. 2005, 103:495-511.
16. Chitalia V.C., Foy R.L., Bachschmid M.M., Zeng L., Panchenko M.V., Zhou M.I., Bharti A., Seldin D.C., Lecker S.H., Dominguez I., Cohen H.T. Jade-1 inhibits Wnt signalling by ubiquitylating beta-catenin and mediates Wnt pathway inhibition by pVHL. Nat. Cell Biol. 2008, 10:1208-1216.
17. Clifford S.C., Cockman M.E., Smallwood A.C., Mole D.R., Woodward E.R., Maxwell P.H., Ratcliffe P.J., Maher E.R. Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Hum. Mol. Genet. 2001, 10:1029-1038.
18. Covassin L.D., Villefranc J.A., Kacergis M.C., Weinstein B.M., Lawson N.D. Distinct genetic interactions between multiple Vegf receptors are required for development of different blood vessel types in zebrafish. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:6554-6559.
19. Cramer T., Yamanishi Y., Clausen B.E., Forster I., Pawlinski R., Mackman N., Haase V.H., Jaenisch R., Corr M., Nizet V., Firestein G.S., Gerber H.P., Ferrara N., Johnson R.S. HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell 2003, 112:645-657.
20. de Jong J.L., Zon L.I. Use of the zebrafish system to study primitive and definitive hematopoiesis. Annu. Rev. Genet. 2005, 39:481-501.
21. Ding M., Cui S., Li C., Jothy S., Haase V., Steer B.M., Marsden P.A., Pippin J., Shankland S., Rastaldi M.P., Cohen C.D., Kretzler M., Quaggin S.E. Loss of the tumor suppressor Vhlh leads to upregulation of Cxcr4 and rapidly progressive glomerulonephritis in mice. Nat. Med. 2006, 12:1081-1087.
22. Doyon Y., McCammon J.M., Miller J.C., Faraji F., Ngo C., Katibah G.E., Amora R., Hocking T.D., Zhang L., Rebar E.J., Gregory P.D., Urnov F.D., Amacher S.L. Heritable targeted gene disruption in zebrafish using designed zinc-finger nucleases. Nat. Biotechnol. 2008, 26:702-708.
23. Drummond I.A. Kidney development and disease in the zebrafish. J. Am. Soc. Nephrol. 2005, 16:299-304.
24. Duan D.R., Pause A., Burgess W.H., Aso T., Chen D.Y., Garrett K.P., Conaway R.C., Conaway J.W., Linehan W.M., Klausner R.D. Inhibition of transcription elongation by the VHL tumor suppressor protein. Science 1995, 269:1402-1406.
25. Ebert B.L., Firth J.D., Ratcliffe P.J. Hypoxia and mitochondrial inhibitors regulate expression of glucose transporter-1 via distinct Cis-acting sequences. J. Biol. Chem. 1995, 270:29083-29089.
26. Eley L., Yates L.M., Goodship J.A. Cilia and disease. Curr. Opin. Genet. Dev. 2005, 15:308-314.
27. Epstein A.C., Gleadle J.M., McNeill L.A., Hewitson K.S., O'Rourke J., Mole D.R., Mukherji M., Metzen E., Wilson M.I., Dhanda A., Tian Y.M., Masson N., Hamilton D.L., Jaakkola P., Barstead R., Hodgkin J., Maxwell P.H., Pugh C.W., Schofield C.J., Ratcliffe P.J. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 2001, 107:43-54.
28. Erler J.T., Bennewith K.L., Nicolau M., Dornhofer N., Kong C., Le Q.T., Chi J.T., Jeffrey S.S., Giaccia A.J. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 2006, 440:1222-1226.
29. Esteban M.A., Harten S.K., Tran M.G., Maxwell P.H. Formation of primary cilia in the renal epithelium is regulated by the von Hippel-Lindau tumor suppressor protein. J. Am. Soc. Nephrol. 2006, 17:1801-1806.
30. Esteban-Barragan M.A., Avila P., Alvarez-Tejado M., Gutierrez M.D., Garcia-Pardo A., Sanchez-Madrid F., Landazuri M.O. Role of the von Hippel-Lindau tumor suppressor gene in the formation of beta1-integrin fibrillar adhesions. Cancer Res. 2002, 62:2929-2936.
31. Fan S., Hurd T.W., Liu C.J., Straight S.W., Weimbs T., Hurd E.A., Domino S.E., Margolis B. Polarity proteins control ciliogenesis via kinesin motor interactions. Curr. Biol. 2004, 14:1451-1461.
32. Feijoo-Cuaresma M., Mendez F., Maqueda A., Esteban M.A., Naranjo-Suarez S., Castellanos M.C., del Cerro M.H., Vazquez S.N., Garcia-Pardo A., Landazuri M.O., Calzada M.J. Inadequate activation of the GTPase RhoA contributes to the lack of fibronectin matrix assembly in von Hippel-Lindau protein-defective renal cancer cells. J. Biol. Chem. 2008, 283:24982-24990.
33. Feitsma H., Cuppen E. Zebrafish as a cancer model. Mol. Cancer Res. 2008, 6:685-694.
34. Forsythe J.A., Jiang B.H., Iyer N.V., Agani F., Leung S.W., Koos R.D., Semenza G.L. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol. 1996, 16:4604-4613.
35. Frew I.J., Krek W. Multitasking by pVHL in tumour suppression. Curr. Opin. Cell Biol. 2007, 19:685-690.
36. Frew I.J., Krek W. pVHL: a multipurpose adaptor protein. Sci. Signal. 2008, 1:pe30.
37. Frew I.J., Minola A., Georgiev S., Hitz M., Moch H., Richard S., Vortmeyer A.O., Krek W. Combined VHLH and PTEN mutation causes genital tract cystadenoma and squamous metaplasia. Mol. Cell. Biol. 2008, 28:4536-4548.
38. Frew I.J., Thoma C.R., Georgiev S., Minola A., Hitz M., Montani M., Moch H., Krek W. pVHL and PTEN tumour suppressor proteins cooperatively suppress kidney cyst formation. EMBO J. 2008, 27:1747-1757.
39. Glasker S., Li J., Xia J.B., Okamoto H., Zeng W., Lonser R.R., Zhuang Z., Oldfield E.H., Vortmeyer A.O. Hemangioblastomas share protein expression with embryonal hemangioblast progenitor cell. Cancer Res. 2006, 66:4167-4172.
40. Gnarra J.R., Ward J.M., Porter F.D., Wagner J.R., Devor D.E., Grinberg A., Emmert-Buck M.R., Westphal H., Klausner R.D., Linehan W.M. Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:9102-9107.
41. Gordeuk V.R., Sergueeva A.I., Miasnikova G.Y., Okhotin D., Voloshin Y., Choyke P.L., Butman J.A., Jedlickova K., Prchal J.T., Polyakova L.A. Congenital disorder of oxygen sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors. Blood 2004, 103:3924-3932.
42. Gordeuk V.R., Stockton D.W., Prchal J.T. Congenital polycythemias/erythrocytoses. Haematologica 2005, 90:109-116.
43. Grosfeld A., Stolze I.P., Cockman M.E., Pugh C.W., Edelmann M., Kessler B., Bullock A.N., Ratcliffe P.J., Masson N. Interaction of hydroxylated collagen IV with the von Hippel-Lindau tumor suppressor. J. Biol. Chem. 2007, 282:13264-13269.
44. Haase V.H. The VHL tumor suppressor in development and disease: functional studies in mice by conditional gene targeting. Semin. Cell Dev. Biol. 2005, 16:564-574.
45. Haase V.H., Glickman J.N., Socolovsky M., Jaenisch R. Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:1583-1588.
46. Hergovich A., Lisztwan J., Barry R., Ballschmieter P., Krek W. Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL. Nat. Cell Biol. 2003, 5:64-70.
47. Herpers R., van de Kamp E., Duckers H.J., Schulte-Merker S. Redundant roles for sox7 and sox18 in arteriovenous specification in zebrafish. Circ. Res. 2008, 102:12-15.
48. Hickey M.M., Lam J.C., Bezman N.A., Rathmell W.K., Simon M.C. von Hippel-Lindau mutation in mice recapitulates Chuvash polycythemia via hypoxia-inducible factor-2alpha signaling and splenic erythropoiesis. J. Clin. Invest. 2007, 117:3879-3889.
49. Hickey M.M., Richardson T., Wang T., Mosqueira M., Arguiri E., Yu H., Yu Q.C., Solomides C.C., Morrisey E.E., Khurana T.S., Christofidou-Solomidou M., Simon M.C. The von Hippel-Lindau Chuvash mutation promotes pulmonary hypertension and fibrosis in mice. J. Clin. Invest. 2010, 120:827-839.
50. Hoffman M.A., Ohh M., Yang H., Klco J.M., Ivan M., Kaelin W.G. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum. Mol. Genet. 2001, 10:1019-1027.
51. Hong S.B., Furihata M., Baba M., Zbar B., Schmidt L.S. Vascular defects and liver damage by the acute inactivation of the VHL gene during mouse embryogenesis. Lab. Invest. 2006, 86:664-675.
52. Hsouna A., Nallamothu G., Kose N., Guinea M., Dammai V., Hsu T. Drosophila von Hippel-Lindau tumor suppressor gene function in epithelial tubule morphogenesis. Mol. Cell. Biol. 2010, 30:3779-3794.
53. Hsu T., Adereth Y., Kose N., Dammai V. Endocytic function of von Hippel-Lindau tumor suppressor protein regulates surface localization of fibroblast growth factor receptor 1 and cell motility. J. Biol. Chem. 2006, 281:12069-12080.
54. Iliopoulos O., Kibel A., Gray S., Kaelin W.G. Tumour suppression by the human von Hippel-Lindau gene product. Nat. Med. 1995, 1:822-826.
55. Iliopoulos O., Ohh M., Kaelin W.G. pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:11661-11666.
56. Ivan M., Kondo K., Yang H., Kim W., Valiando J., Ohh M., Salic A., Asara J.M., Lane W.S., Kaelin W.G. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001, 292:464-468.
57. Jaakkola P., Mole D.R., Tian Y.M., Wilson M.I., Gielbert J., Gaskell S.J., Kriegsheim A., Hebestreit H.F., Mukherji M., Schofield C.J., Maxwell P.H., Pugh C.W., Ratcliffe P.J. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001, 292:468-472.
58. Jarrell S.T., Vortmeyer A.O., Linehan W.M., Oldfield E.H., Lonser R.R. Metastases to hemangioblastomas in von Hippel-Lindau disease. J. Neurosurg. 2006, 105:256-263.
59. Jonz M.G., Nurse C.A. Development of oxygen sensing in the gills of zebrafish. J. Exp. Biol. 2005, 208:1537-1549.
60. Kaelin W.G. The von Hippel-Lindau tumor suppressor protein: roles in cancer and oxygen sensing. Cold Spring Harb. Symp. Quant. Biol. 2005, 70:159-166.
61. Kaelin W.G. The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin. Cancer Res. 2007, 13:680s-684s.
62. Kamura T., Koepp D.M., Conrad M.N., Skowyra D., Moreland R.J., Iliopoulos O., Lane W.S., Kaelin W.G., Elledge S.J., Conaway R.C., Harper J.W., Conaway J.W. Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science 1999, 284:657-661.
63. Karhausen J., Furuta G.T., Tomaszewski J.E., Johnson R.S., Colgan S.P., Haase V.H. Epithelial hypoxia-inducible factor-1 is protective in murine experimental colitis. J. Clin. Invest. 2004, 114:1098-1106.
64. Kibel A., Iliopoulos O., DeCaprio J.A., Kaelin W.G. Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C. Science 1995, 269:1444-1446.
65. Kikuchi Y., Kobayashi E., Nishizawa M., Hamazaki S., Okada S., Hino O. Cloning of the rat homologue of the von Hippel-Lindau tumor suppressor gene and its non-somatic mutation in rat renal cell carcinomas. Jpn. J. Cancer Res. 1995, 86:905-909.
66. Kim W.Y., Kaelin W.G. Role of VHL gene mutation in human cancer. J. Clin. Oncol. 2004, 22:4991-5004.
67. Kleymenova E., Everitt J.I., Pluta L., Portis M., Gnarra J.R., Walker C.L. Susceptibility to vascular neoplasms but no increased susceptibility to renal carcinogenesis in Vhl knockout mice. Carcinogenesis 2004, 25:309-315.
68. Knudson A.G. Mutation and cancer: statistical study of retinoblastoma. Proc. Natl. Acad. Sci. U. S. A. 1971, 68:820-823.
69. Koivunen P., Hirsila M., Gunzler V., Kivirikko K.I., Myllyharju J. Catalytic properties of the asparaginyl hydroxylase (FIH) in the oxygen sensing pathway are distinct from those of its prolyl 4-hydroxylases. J. Biol. Chem. 2004, 279:9899-9904.
70. Koochekpour S., Jeffers M., Wang P.H., Gong C., Taylor G.A., Roessler L.M., Stearman R., Vasselli J.R., Stetler-Stevenson W.G., Kaelin W.G., Linehan W.M., Klausner R.D., Gnarra J.R., Vande Woude G.F. The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells. Mol. Cell. Biol. 1999, 19:5902-5912.
71. Kryczek I., Lange A., Mottram P., Alvarez X., Cheng P., Hogan M., Moons L., Wei S., Zou L., Machelon V., Emilie D., Terrassa M., Lackner A., Curiel T.J., Carmeliet P., Zou W. CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Res. 2005, 65:465-472.
72. Kuehn E.W., Walz G., Benzing T. von Hippel-Lindau: a tumor suppressor links microtubules to ciliogenesis and cancer development. Cancer Res. 2007, 67:4537-4540.
73. Kurban G., Duplan E., Ramlal N., Hudon V., Sado Y., Ninomiya Y., Pause A. Collagen matrix assembly is driven by the interaction of von Hippel-Lindau tumor suppressor protein with hydroxylated collagen IV alpha 2. Oncogene 2008, 27:1004-1012.
74. Kurban G., Hudon V., Duplan E., Ohh M., Pause A. Characterization of a von Hippel Lindau pathway involved in extracellular matrix remodeling, cell invasion, and angiogenesis. Cancer Res. 2006, 66:1313-1319.
75. Lach B., Gregor A., Rippstein P., Omulecka A. Angiogenic histogenesis of stromal cells in hemangioblastoma: ultrastructural and immunohistochemical study. Ultrastruct. Pathol. 1999, 23:299-310.
76. Latif F., Tory K., Gnarra J., Yao M., Duh F.M., Orcutt M.L., Stackhouse T., Kuzmin I., Modi W., Geil L., et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993, 260:1317-1320.
77. Lee S., Nakamura E., Yang H., Wei W., Linggi M.S., Sajan M.P., Farese R.V., Freeman R.S., Carter B.D., Kaelin W.G., Schlisio S. Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell 2005, 8:155-167.
78. Lei L., Mason S., Liu D., Huang Y., Marks C., Hickey R., Jovin I.S., Pypaert M., Johnson R.S., Giordano F.J. Hypoxia-inducible factor-dependent degeneration, failure, and malignant transformation of the heart in the absence of the von Hippel-Lindau protein. Mol. Cell. Biol. 2008, 28:3790-3803.
79. Lieschke G.J., Currie P.D. Animal models of human disease: zebrafish swim into view. Nat. Rev. Genet. 2007, 8:353-367.
80. Lolkema M.P., Mans D.A., Snijckers C.M., van Noort M., van Beest M., Voest E.E., Giles R.H. The von Hippel-Lindau tumour suppressor interacts with microtubules through kinesin-2. FEBS Lett. 2007, 581:4571-4576.
81. Lolkema M.P., Mans D.A., Ulfman L.H., Volpi S., Voest E.E., Giles R.H. Allele-specific regulation of primary cilia function by the von Hippel-Lindau tumor suppressor. Eur. J. Hum. Genet. 2008, 16:73-78.
82. Lonser R.R., Glenn G.M., Walther M., Chew E.Y., Libutti S.K., Linehan W.M., Oldfield E.H. von Hippel-Lindau disease. Lancet 2003, 361:2059-2067.
83. Lutz M.S., Burk R.D. Primary cilium formation requires von Hippel-Lindau gene function in renal-derived cells. Cancer Res. 2006, 66:6903-6907.
84. Ma W., Tessarollo L., Hong S.B., Baba M., Southon E., Back T.C., Spence S., Lobe C.G., Sharma N., Maher G.W., Pack S., Vortmeyer A.O., Guo C., Zbar B., Schmidt L.S. Hepatic vascular tumors, angiectasis in multiple organs, and impaired spermatogenesis in mice with conditional inactivation of the VHL gene. Cancer Res. 2003, 63:5320-5328.
85. Ma A.C., Ward A.C., Liang R., Leung A.Y. The role of jak2a in zebrafish hematopoiesis. Blood 2007, 110:1824-1830.
86. Maher E.R., Iselius L., Yates J.R., Littler M., Benjamin C., Harris R., Sampson J., Williams A., Ferguson-Smith M.A., Morton N. von Hippel-Lindau disease: a genetic study. J. Med. Genet. 1991, 28:443-447.
87. Maher E.R., Kaelin W.G. von Hippel-Lindau disease. Medicine (Baltimore) 1997, 76:381-391.
88. Maher E.R., Yates J.R., Harries R., Benjamin C., Harris R., Moore A.T., Ferguson-Smith M.A. Clinical features and natural history of von Hippel-Lindau disease. Q. J. Med. 1990, 77:1151-1163.
89. Mahon P.C., Hirota K., Semenza G.L. FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev. 2001, 15:2675-2686.
90. Mandriota S.J., Turner K.J., Davies D.R., Murray P.G., Morgan N.V., Sowter H.M., Wykoff C.C., Maher E.R., Harris A.L., Ratcliffe P.J., Maxwell P.H. HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 2002, 1:459-468.
91. Maxwell P.H., Wiesener M.S., Chang G.W., Clifford S.C., Vaux E.C., Cockman M.E., Wykoff C.C., Pugh C.W., Maher E.R., Ratcliffe P.J. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999, 399:271-275.
92. McGrath F.P., Gibney R.G., Morris D.C., Owen D.A., Erb S.R. Case report: multiple hepatic and pulmonary haemangioblastomas - a new manifestation of von Hippel-Lindau disease. Clin. Radiol. 1992, 45:37-39.
93. Mehta G.U., Shively S.B., Duong H., Tran M.G., Moncrief T.J., Smith J.H., Li J., Edwards N.A., Lonser R.R., Zhuang Z., Merrill M.J., Raffeld M., Maxwell P.H., Oldfield E.H., Vortmeyer A.O. Progression of epididymal maldevelopment into hamartoma-like neoplasia in VHL disease. Neoplasia 2008, 10:1146-1153.
94. Meng X., Noyes M.B., Zhu L.J., Lawson N.D., Wolfe S.A. Targeted gene inactivation in zebrafish using engineered zinc-finger nucleases. Nat. Biotechnol. 2008, 26:695-701.
95. Mikhaylova O., Ignacak M.L., Barankiewicz T.J., Harbaugh S.V., Yi Y., Maxwell P.H., Schneider M., Van Geyte K., Carmeliet P., Revelo M.P., Wyder M., Greis K.D., Meller J., Czyzyk-Krzeska M.F. The von Hippel-Lindau tumor suppressor protein and Egl-9-type proline hydroxylases regulate the large subunit of RNA polymerase II in response to oxidative stress. Mol. Cell. Biol. 2008, 28:2701-2717.
96. Minchenko A., Leshchinsky I., Opentanova I., Sang N., Srinivas V., Armstead V., Caro J. Hypoxia-inducible factor-1-mediated expression of the 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3) gene. Its possible role in the Warburg effect. J. Biol. Chem. 2002, 277:6183-6187.
97. Motzer R.J., Bander N.H., Nanus D.M. Renal-cell carcinoma. N. Engl. J. Med. 1996, 335:865-875.
98. Neumann H.P., Wiestler O.D. Clustering of features of von Hippel-Lindau syndrome: evidence for a complex genetic locus. Lancet 1991, 337:1052-1054.
99. Neumann A.K., Yang J., Biju M.P., Joseph S.K., Johnson R.S., Haase V.H., Freedman B.D., Turka L.A. Hypoxia inducible factor 1 alpha regulates T cell receptor signal transduction. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:17071-17076.
100. Nordstrom-O'Brien M., van der Luijt R.B., van Rooijen E., van den Ouweland A.M., Majoor-Krakauer D.F., Lolkema M.P., van Brussel A., Voest E.E., Giles R.H. Genetic analysis of von Hippel-Lindau disease. Hum. Mutat. 2010, 31:521-537.
101. Ohh M., Yauch R.L., Lonergan K.M., Whaley J.M., Stemmer-Rachamimov A.O., Louis D.N., Gavin B.J., Kley N., Kaelin W.G., Iliopoulos O. The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol. Cell 1998, 1:959-968.
102. Paffett-Lugassy N., Hsia N., Fraenkel P.G., Paw B., Leshinsky I., Barut B., Bahary N., Caro J., Handin R., Zon L.I. Functional conservation of erythropoietin signaling in zebrafish. Blood 2007, 110:2718-2726.
103. Pause A., Lee S., Worrell R.A., Chen D.Y., Burgess W.H., Linehan W.M., Klausner R.D. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:2156-2161.
104. Peyssonnaux C., Zinkernagel A.S., Schuepbach R.A., Rankin E., Vaulont S., Haase V.H., Nizet V., Johnson R.S. Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J. Clin. Invest. 2007, 117:1926-1932.
105. Pfander D., Kobayashi T., Knight M.C., Zelzer E., Chan D.A., Olsen B.R., Giaccia A.J., Johnson R.S., Haase V.H., Schipani E. Deletion of Vhlh in chondrocytes reduces cell proliferation and increases matrix deposition during growth plate development. Development 2004, 131:2497-2508.
106. Pocock R., Hobert O. Oxygen levels affect axon guidance and neuronal migration in Caenorhabditis elegans. Nat. Neurosci. 2008, 11:894-900.
107. Qi H., Gervais M.L., Li W., DeCaprio J.A., Challis J.R., Ohh M. Molecular cloning and characterization of the von Hippel-Lindau-like protein. Mol. Cancer Res. 2004, 2:43-52.
108. Rankin E.B., Higgins D.F., Walisser J.A., Johnson R.S., Bradfield C.A., Haase V.H. Inactivation of the arylhydrocarbon receptor nuclear translocator (Arnt) suppresses von Hippel-Lindau disease-associated vascular tumors in mice. Mol. Cell. Biol. 2005, 25:3163-3172.
109. Rankin E.B., Tomaszewski J.E., Haase V.H. Renal cyst development in mice with conditional inactivation of the von Hippel-Lindau tumor suppressor. Cancer Res. 2006, 66:2576-2583.
110. Richard S., David P., Marsot-Dupuch K., Giraud S., Beroud C., Resche F. Central nervous system hemangioblastomas, endolymphatic sac tumors, and von Hippel-Lindau disease. Neurosurg. Rev. 2000, 23:1-22. discussion 23-24.
111. Roe J.S., Kim H., Lee S.M., Kim S.T., Cho E.J., Youn H.D. p53 stabilization and transactivation by a von Hippel-Lindau protein. Mol. Cell 2006, 22:395-405.
112. Rojiani A.M., Owen D.A., Berry K., Woodhurst B., Anderson F.H., Scudamore C.H., Erb S. Hepatic hemangioblastoma. An unusual presentation in a patient with von Hippel-Lindau disease. Am. J. Surg. Pathol. 1991, 15:81-86.
113. Ruas J.L., Poellinger L. Hypoxia-dependent activation of HIF into a transcriptional regulator. Semin. Cell Dev. Biol. 2005, 16:514-522.
114. Schermer B., Ghenoiu C., Bartram M., Muller R.U., Kotsis F., Hohne M., Kuhn W., Rapka M., Nitschke R., Zentgraf H., Fliegauf M., Omran H., Walz G., Benzing T. The von Hippel-Lindau tumor suppressor protein controls ciliogenesis by orienting microtubule growth. J. Cell Biol. 2006, 175:547-554.
115. Schoenfeld A., Davidowitz E.J., Burk R.D. A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:8817-8822.
116. Seizinger B.R., Rouleau G.A., Ozelius L.J., Lane A.H., Farmer G.E., Lamiell J.M., Haines J., Yuen J.W., Collins D., Majoor-Krakauer D., et al. von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature 1988, 332:268-269.
117. Semenza G.L. HIF-1, O(2), and the 3 PHDs: how animal cells signal hypoxia to the nucleus. Cell 2001, 107:1-3.
118. Semenza G.L. Regulation of vascularization by hypoxia-inducible factor 1. Ann. N. Y. Acad. Sci. 2009, 1177:2-8.
119. Semenza G.L., Roth P.H., Fang H.M., Wang G.L. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J. Biol. Chem. 1994, 269:23757-23763.
120. Shen C., Nettleton D., Jiang M., Kim S.K., Powell-Coffman J.A. Roles of the HIF-1 hypoxia-inducible factor during hypoxia response in Caenorhabditis elegans. J. Biol. Chem. 2005, 280:20580-20588.
121. Shiao Y.H., Diwan B.A., Perantoni A.O., Calvert R.J., Zbar B., Lerman M.I., Rice J.M. Polymerase chain reaction-single-strand conformation polymorphism analysis for the VHL gene in chemically induced kidney tumors of rats using intron-derived primers. Mol. Carcinog. 1997, 19:230-235.
122. Shively S., Beltaifa S., Gehrs B., Duong H., Smith J., Edwards N., Lonser R., Raffeld M., Vortmeyer A. Protracted haemangioblastic proliferation and differentiation in von Hippel-Lindau disease. J. Pathol. 2008, 216:514-520.
123. Siekmann A.F., Standley C., Fogarty K.E., Wolfe S.A., Lawson N.D. Chemokine signaling guides regional patterning of the first embryonic artery. Genes Dev. 2009, 23:2272-2277.
124. Smith T.G., Brooks J.T., Balanos G.M., Lappin T.R., Layton D.M., Leedham D.L., Liu C., Maxwell P.H., McMullin M.F., McNamara C.J., Percy M.J., Pugh C.W., Ratcliffe P.J., Talbot N.P., Treacy M., Robbins P.A. Mutation of von Hippel-Lindau tumour suppressor and human cardiopulmonary physiology. PLoS Med. 2006, 3:e290.
125. Song H.D., Sun X.J., Deng M., Zhang G.W., Zhou Y., Wu X.Y., Sheng Y., Chen Y., Ruan Z., Jiang C.L., Fan H.Y., Zon L.I., Kanki J.P., Liu T.X., Look A.T., Chen Z. Hematopoietic gene expression profile in zebrafish kidney marrow. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:16240-16245.
126. Staller P., Sulitkova J., Lisztwan J., Moch H., Oakeley E.J., Krek W. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 2003, 425:307-311.
127. Stickle N.H., Chung J., Klco J.M., Hill R.P., Kaelin W.G., Ohh M. pVHL modification by NEDD8 is required for fibronectin matrix assembly and suppression of tumor development. Mol. Cell. Biol. 2004, 24:3251-3261.
128. Tang N., Mack F., Haase V.H., Simon M.C., Johnson R.S. pVHL function is essential for endothelial extracellular matrix deposition. Mol. Cell. Biol. 2006, 26:2519-2530.
129. Tang N., Wang L., Esko J., Giordano F.J., Huang Y., Gerber H.P., Ferrara N., Johnson R.S. Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell 2004, 6:485-495.
130. Taraboletti G., Giavazzi R. Modelling approaches for angiogenesis. Eur. J. Cancer 2004, 40:881-889.
131. Thoma C.R., Frew I.J., Hoerner C.R., Montani M., Moch H., Krek W. pVHL and GSK3beta are components of a primary cilium-maintenance signalling network. Nat. Cell Biol. 2007, 9:588-595.
132. Thoma C.R., Toso A., Gutbrodt K.L., Reggi S.P., Frew I.J., Schraml P., Hergovich A., Moch H., Meraldi P., Krek W. VHL loss causes spindle misorientation and chromosome instability. Nat. Cell Biol. 2009, 11:994-1001.
133. Treinin M., Shliar J., Jiang H., Powell-Coffman J.A., Bromberg Z., Horowitz M. HIF-1 is required for heat acclimation in the nematode Caenorhabditis elegans. Physiol. Genomics 2003, 14:17-24.
134. Van Poppel H., Nilsson S., Algaba F., Bergerheim U., Dal Cin P., Fleming S., Hellsten S., Kirkali Z., Klotz L., Lindblad P., Ljungberg B., Mulders P., Roskams T., Ross R.K., Walker C., Wersall P. Precancerous lesions in the kidney. Scand. J. Urol. Nephrol. Suppl. 2000, 136-165.
135. van Rooijen E., Voest E.E., Logister I., Bussmann J., Korving J., van Eeden F.J., Giles R.H., Schulte-Merker S. von Hippel-Lindau tumor suppressor mutants faithfully model pathological hypoxia-driven angiogenesis and vascular retinopathies in zebrafish. Dis. Model Mech. 2010, 3:343-353.
136. van Rooijen E., Voest E.E., Logister I., Korving J., Schwerte T., Schulte-Merker S., Giles R.H., van Eeden F.J. Zebrafish mutants in the von Hippel-Lindau tumor suppressor display a hypoxic response and recapitulate key aspects of Chuvash polycythemia. Blood 2009, 113:6449-6460.
137. Vogel A.M., Weinstein B.M. Studying vascular development in the zebrafish. Trends Cardiovasc. Med. 2000, 10:352-360.
138. Walker C., Ahn Y.T., Everitt J., Yuan X. Renal cell carcinoma development in the rat independent of alterations at the VHL gene locus. Mol. Carcinog. 1996, 15:154-161.
139. Walther M.M., Lubensky I.A., Venzon D., Zbar B., Linehan W.M. Prevalence of microscopic lesions in grossly normal renal parenchyma from patients with von Hippel-Lindau disease, sporadic renal cell carcinoma and no renal disease: clinical implications. J. Urol. 1995, 154:2010-2014. discussion 2014-2015.
140. Wang Y., Roche O., Yan M.S., Finak G., Evans A.J., Metcalf J.L., Hast B.E., Hanna S.C., Wondergem B., Furge K.A., Irwin M.S., Kim W.Y., Teh B.T., Grinstein S., Park M., Marsden P.A., Ohh M. Regulation of endocytosis via the oxygen-sensing pathway. Nat. Med. 2009, 15:319-324.
141. Wang Y., Wan C., Deng L., Liu X., Cao X., Gilbert S.R., Bouxsein M.L., Faugere M.C., Guldberg R.E., Gerstenfeld L.C., Haase V.H., Johnson R.S., Schipani E., Clemens T.L. The hypoxia-inducible factor alpha pathway couples angiogenesis to osteogenesis during skeletal development. J. Clin. Invest. 2007, 117:1616-1626.
142. Welford S.M., Dorie M.J., Li X., Haase V.H., Giaccia A.J. Renal oxygenation suppresses VHL-loss-induced senescence that is caused by increased sensitivity to oxidative stress. Mol. Cell. Biol. 2010, 30:4595-4603.
143. Wenger R.H. Cellular adaptation to hypoxia: O2-sensing protein hydroxylases, hypoxia-inducible transcription factors, and O2-regulated gene expression. FASEB J. 2002, 16:1151-1162.
144. Wienholds E., van Eeden F., Kosters M., Mudde J., Plasterk R.H., Cuppen E. Efficient target-selected mutagenesis in zebrafish. Genome Res. 2003, 13:2700-2707.
145. Wingert R.A., Davidson A.J. The zebrafish pronephros: a model to study nephron segmentation. Kidney Int. 2008, 73:1120-1127.
146. Yang H., Minamishima Y.A., Yan Q., Schlisio S., Ebert B.L., Zhang X., Zhang L., Kim W.Y., Olumi A.F., Kaelin W.G. pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2. Mol. Cell 2007, 28:15-27.
147. Yaqoob N., Schwerte T. Cardiovascular and respiratory developmental plasticity under oxygen depleted environment and in genetically hypoxic zebrafish (Danio rerio). Comp. Biochem. Physiol. A Mol. Integr. Physiol. 2010, 156:475-484.
148. Yoshimura A., Misawa H. Physiology and function of the erythropoietin receptor. Curr. Opin. Hematol. 1998, 5:171-176.
149. Young A.P., Schlisio S., Minamishima Y.A., Zhang Q., Li L., Grisanzio C., Signoretti S., Kaelin W.G. VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400. Nat. Cell Biol. 2008, 10:361-369.
150. Zagzag D., Krishnamachary B., Yee H., Okuyama H., Chiriboga L., Ali M.A., Melamed J., Semenza G.L. Stromal cell-derived factor-1alpha and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel-Lindau loss-of-function induces expression of a ligand and its receptor. Cancer Res. 2005, 65:6178-6188.
151. Zbar B., Kishida T., Chen F., Schmidt L., Maher E.R., Richards F.M., Crossey P.A., Webster A.R., Affara N.A., Ferguson-Smith M.A., Brauch H., Glavac D., Neumann H.P., Tisherman S., Mulvihill J.J., Gross D.J., Shuin T., Whaley J., Seizinger B., Kley N., Olschwang S., Boisson C., Richard S., Lips C.H., Lerman M., et al. Germline mutations in the von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. Hum. Mutat. 1996, 8:348-357.
152. Zehetner J., Danzer C., Collins S., Eckhardt K., Gerber P.A., Ballschmieter P., Galvanovskis J., Shimomura K., Ashcroft F.M., Thorens B., Rorsman P., Krek W. PVHL is a regulator of glucose metabolism and insulin secretion in pancreatic beta cells. Genes Dev. 2008, 22:3135-3146.